|
Andrew is an investor and entrepreneur with 17 years of experience building, restructuring and acquiring companies in life science arena. A founding member of our venture fund, Andrew is also an active advisor to InCube Labs, LLC.
Prior to joining the venture fund, Andrew was an active investor with The Angels’ Forum and a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments include Intrapace (obesity), Penumbra (ischemic stroke), Sonoma Orthopedic Products (bone repair), SwitchGear Genomics (gene regulation) & Spinal Modulation (pain management).
Earlier in his career, Andrew served as Senior Vice President of sales, marketing and research for QIAGEN Operon. During his tenure there, Andrew built a global sales force from scratch and launched the world's first microarray products for whole-genome analysis of the malaria and tuberculosis genomes. Along the way, he grew revenues of synthetic DNA products from $13 to $40M in two years, and played a key role in selling the business for nine figures. He subsequently acquired a company in Japan for QIAGEN, and restructured the genomics sales force of the merged entities. In his earlier career, Andrew held several roles in research operations at Genentech, Inc. and co-founded a gene design business in agricultural biotechnology. He has also founded several other companies, sat on a range of boards, and developed strategies for healthcare firms as a consultant.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor’s with high honors from the University of California at Berkeley.
|
